Table 2.

Thalidomide doses and response

Patient no.Treatment duration, wkFinal dose, mg/dResponse to thalidomideToxicity (WHO grade)
40 400 PR Constipation (2)  
15 400 No response Constipation (1) 
19 200 PR Constipation (2) 
400 Withdrawal (early progression) N/A 
14 200 HI Constipation (3) 
200 Withdrawal (drug intolerance) Neuropathy (2) 
200 Withdrawal (personal decision) Fatigue (1) 
400 Withdrawal (personal decision) Fatigue (2), rash (2)  
200 Withdrawal (early progression) Fatigue (2)  
10 400 No response Fatigue (1), constipation (2) 
11 200 PR Fatigue (1), rash (2), neuropathy (2) 
12 400 No response Constipation (2) 
13 200 Progression Fatigue (2), neuropathy (1) 
14 200 Withdrawal (early progression) Rash (2) 
15 200 Progression Fatigue (1), constipation (2), rash (1)  
16 11 200 No response Fatigue (2) 
17 200 Progression Fatigue (1), constipation (2) 
18 200 Withdrawal (drug intolerance) Fatigue (1), neuropathy (2)  
19 200 No response Fatigue (2) 
20 200 PR Fatigue (1), constipation (2), rash (1) 
Patient no.Treatment duration, wkFinal dose, mg/dResponse to thalidomideToxicity (WHO grade)
40 400 PR Constipation (2)  
15 400 No response Constipation (1) 
19 200 PR Constipation (2) 
400 Withdrawal (early progression) N/A 
14 200 HI Constipation (3) 
200 Withdrawal (drug intolerance) Neuropathy (2) 
200 Withdrawal (personal decision) Fatigue (1) 
400 Withdrawal (personal decision) Fatigue (2), rash (2)  
200 Withdrawal (early progression) Fatigue (2)  
10 400 No response Fatigue (1), constipation (2) 
11 200 PR Fatigue (1), rash (2), neuropathy (2) 
12 400 No response Constipation (2) 
13 200 Progression Fatigue (2), neuropathy (1) 
14 200 Withdrawal (early progression) Rash (2) 
15 200 Progression Fatigue (1), constipation (2), rash (1)  
16 11 200 No response Fatigue (2) 
17 200 Progression Fatigue (1), constipation (2) 
18 200 Withdrawal (drug intolerance) Fatigue (1), neuropathy (2)  
19 200 No response Fatigue (2) 
20 200 PR Fatigue (1), constipation (2), rash (1) 

WHO indicates World Health Organization; PR, partial response; NA, not applicable; and HI, hematologic improvement.

Close Modal

or Create an Account

Close Modal
Close Modal